Department of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands
Search for other papers by Josephina G Kuiper in
Google Scholar
PubMed
Department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
Search for other papers by Aline C Fenneman in
Google Scholar
PubMed
Search for other papers by Anne H van der Spek in
Google Scholar
PubMed
Search for other papers by Elena Rampanelli in
Google Scholar
PubMed
Department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
Search for other papers by Max Nieuwdorp in
Google Scholar
PubMed
Search for other papers by Myrthe P P van Herk-Sukel in
Google Scholar
PubMed
Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands
Search for other papers by Valery E P P Lemmens in
Google Scholar
PubMed
Search for other papers by Ernst J Kuipers in
Google Scholar
PubMed
Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, Netherlands
Search for other papers by Ron M C Herings in
Google Scholar
PubMed
Search for other papers by Eric Fliers in
Google Scholar
PubMed
.nivel.nl/nl/nivel-zorgregistraties-eerste-lijn/jaarcijfers-aandoeningen-incidenties-en-prevalenties ). Treatment of primary hypothyroidism consists of hormone substitution therapy with daily oral administration of the synthetic thyroid hormone levothyroxine. The majority of levothyroxine is absorbed in the upper gastrointestinal tract, ranging from 40 to 80
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Bjarke R Medici in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Birte Nygaard in
Google Scholar
PubMed
Search for other papers by Jeppe L la Cour in
Google Scholar
PubMed
Department of Clinical Physiology and Nuclear Medicine, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Martin Krakauer in
Google Scholar
PubMed
Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Andreas Brønden in
Google Scholar
PubMed
Search for other papers by Mette P Sonne in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Jens J Holst in
Google Scholar
PubMed
Search for other papers by Jens F Rehfeld in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Steno Diabetes Center Copenhagen, Herlev, Denmark
Search for other papers by Tina Vilsbøll in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Jens Faber in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Steno Diabetes Center Copenhagen, Herlev, Denmark
Search for other papers by Filip K Knop in
Google Scholar
PubMed
Introduction Hypothyroidism is a common endocrine disease, affecting about 3% of the general population ( 1 ), with levothyroxine substitution therapy being the standard treatment ( 2 , 3 ). Hypothyroidism is associated with increased body
Search for other papers by Salman Razvi in
Google Scholar
PubMed
Search for other papers by Sanaa Mrabeti in
Google Scholar
PubMed
Search for other papers by Markus Luster in
Google Scholar
PubMed
Introduction Current management guidelines for the management of hypothyroidism focus on the administration of levothyroxine (LT4), with doses titrated to bring thyroid-stimulating hormone (thyrotropin, TSH) within a locally-derived reference
Search for other papers by Bogumila Urgatz in
Google Scholar
PubMed
Search for other papers by Kris G Poppe in
Google Scholar
PubMed
recommend measuring TSH in women with TAB at the time of confirmation of pregnancy and monthly during mid-pregnancy ( 8 ). Effects of levothyroxine during pregnancy A large database study of 1013 pregnancies in the UK, where LT4 was started at least
Search for other papers by Nella Augusta Greggio in
Google Scholar
PubMed
Search for other papers by Elisa Rossi in
Google Scholar
PubMed
Search for other papers by Silvia Calabria in
Google Scholar
PubMed
Search for other papers by Alice Meneghin in
Google Scholar
PubMed
Search for other papers by Joaquin Gutierrez de Rubalcava in
Google Scholar
PubMed
Search for other papers by Carlo Piccinni in
Google Scholar
PubMed
Search for other papers by Antonella Pedrini in
Google Scholar
PubMed
, 12 , 13 , 14 , 15 , 16 , 17 ). For this reason, the available European guidelines are not definitive on treatment of this population: it generally recommends a treatment with levothyroxine in children aged <3 years, in order to support the
Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam, The Netherlands
Amsterdam UMC location University of Amsterdam, Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam, The Netherlands
Search for other papers by Heleen I Jansen in
Google Scholar
PubMed
Search for other papers by Marijn M Bult in
Google Scholar
PubMed
Amsterdam UMC location University of Amsterdam, Department of Endocrinology and Metabolism, Amsterdam, The Netherlands
Search for other papers by Peter H Bisschop in
Google Scholar
PubMed
Amsterdam UMC location University of Amsterdam, Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam, The Netherlands
Amsterdam Reproduction & Development Research Institute, Amsterdam, The Netherlands
Search for other papers by Anita Boelen in
Google Scholar
PubMed
Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam, The Netherlands
Amsterdam UMC location University of Amsterdam, Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam, The Netherlands
Amsterdam Reproduction & Development Research Institute, Amsterdam, The Netherlands
Search for other papers by Annemieke C Heijboer in
Google Scholar
PubMed
Amsterdam UMC location University of Amsterdam, Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam, The Netherlands
Search for other papers by Jacquelien J Hillebrand in
Google Scholar
PubMed
samples with fT4 > ULN and a slightly suppressed TSH and 72% of the samples with fT4 > ULN and a TSH within the reference interval belonged to levothyroxine (L-T4) users, as shown in Fig. 1 . Furthermore, we noticed that, respectively, 4.7 and 8.2% of the
Search for other papers by Nikolina Zdraveska in
Google Scholar
PubMed
Search for other papers by Maja Zdravkovska in
Google Scholar
PubMed
Search for other papers by Violeta Anastasovska in
Google Scholar
PubMed
Search for other papers by Elena Sukarova-Angelovska in
Google Scholar
PubMed
Search for other papers by Mirjana Kocova in
Google Scholar
PubMed
initiated on levothyroxine (LT 4 ) treatment. The patients underwent regular thyroid function tests (TFT), as well as assessment of growth and development, mainly at 3-month intervals. Children aged ≥3 years underwent trial off therapy for period of 4 weeks
Search for other papers by Carmen Sydlik in
Google Scholar
PubMed
Search for other papers by Ilja Dubinski in
Google Scholar
PubMed
Search for other papers by Susanne Bechtold in
Google Scholar
PubMed
Search for other papers by Heinrich Schmidt in
Google Scholar
PubMed
hypothyroidism. Therefore, thyroxine/free thyroxine (T4/fT4) levels are used as an additional parameter for therapy adjustment in patients treated with levothyroxine (LT4). However, peripheral euthyroidism cannot be reliably assessed even with both parameters
Search for other papers by Ning Yuan in
Google Scholar
PubMed
Search for other papers by Jianbin Sun in
Google Scholar
PubMed
Search for other papers by Xin Zhao in
Google Scholar
PubMed
Search for other papers by Jing Du in
Google Scholar
PubMed
Search for other papers by Min Nan in
Google Scholar
PubMed
Search for other papers by Qiaoling Zhang in
Google Scholar
PubMed
Search for other papers by Xiaomei Zhang in
Google Scholar
PubMed
(GDM), and placental abruption ( 1 , 2 , 3 ). A previous study ( 4 ) about thyroid disease and pregnancy outcomes showed that SCH increased the odds of adverse pregnancy outcomes and that levothyroxine (LT4) administration improved pregnancy outcomes
Department of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China
Search for other papers by Ningning Gong in
Google Scholar
PubMed
Search for other papers by Cuixia Gao in
Google Scholar
PubMed
Search for other papers by Xuedi Chen in
Google Scholar
PubMed
Search for other papers by Yu Wang in
Google Scholar
PubMed
Search for other papers by Limin Tian in
Google Scholar
PubMed
-α levels with endothelial function and the development of sHT with different TSH levels have not yet been investigated. Moreover, the effect of levothyroxine (LT 4 ) treatment on adipokine levels and endothelial function is not yet clear. Our study aims to